Jiangsu Hengrui Medicine Co., Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Jiangsu Hengrui Medicine Co., Ltd.
10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.
BeiGene co-founder and chair of the major global biotech's Scientific Advisory Board, Dr. Xiaodong Wang, sits down with Scrip in an exclusive audio interview to shed light on the rapid rise of China's biotech innovation, the country's role in BeiGene's global strategy and the next big things to watch.
Jiangsu Vcare Pharmatech, Neurodawn Pharmaceutical and Shanghai Synvida Biotechnology stand out with funding rounds that each grossed roughly CNY200m ($28m) and above.
Immuno-oncology will remain a major force at both FDA’s drugs and biologics centers, but watch for psychiatry and antibiotics to make some noise; rare pediatric diseases will remain prominent as the priority review voucher program heads into the sunset.
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- Atridia Pty Ltd
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Hengrui Therapeutics, Inc., Hengrui Pharmaceuticals, Fujian Shengdi Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.